Ginkgo Bioworks
DNA
174 hedge funds and large institutions have $197M invested in Ginkgo Bioworks in 2026 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 53 increasing their positions, 42 reducing their positions, and 28 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 42
13% more call options, than puts
Call options by funds: $1.79M | Put options by funds: $1.59M
7% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 28
2.28% less ownership
Funds ownership: 67.03% → 64.74% (-2.3%)
3% less funds holding
Funds holding: 180 → 174 (-6)
27% less capital invested
Capital invested by funds: $270M → $197M (-$73.3M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.65M |
| 2 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$2.25M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
+$2.09M |
| 4 |
N
Numerai
San Francisco,
California
|
+$1.25M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.55M |
| 2 |
LIM
Lingotto Investment Management
London,
United Kingdom
|
-$2.08M |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$1.88M |
| 4 |
Jane Street
New York
|
-$1.51M |
| 5 |
GCM
Glenview Capital Management
New York
|
-$1.24M |
DNA Hedge Fund Activity: Q1 2026 in Review
174 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks (DNA) for Q1 2026, worth a combined $197M — down 27% from $270M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new DNA positions and 28 closed out — a net gain of 2 holders — while 53 added to existing stakes and 42 trimmed.
The largest buyer was Millennium Management, adding an estimated $3.65M. The largest seller was Morgan Stanley, cutting an estimated $2.55M.
- 174 institutional investors held Ginkgo Bioworks (DNA) as of Q1 2026, down from 180 in Q4 2025.
- Funds reported $197M of Ginkgo Bioworks stock for Q1 2026, down 27% quarter-over-quarter.
- 30 funds opened new Ginkgo Bioworks positions in Q1 2026 and 28 closed out, a net change of +2 holders.
- The largest Ginkgo Bioworks buyer in Q1 2026 was Millennium Management, an estimated $3.65M added.
- The largest Ginkgo Bioworks seller in Q1 2026 was Morgan Stanley, an estimated $2.55M sold.
Based on aggregated 13F filings for Q1 2026.